鱼油降脂丸治疗高脂血症的临床疗效观察

Clinical Efficacy of Fish Oil in the Treatment of Hyperlipidemia

观察了30例高脂血症患者口服鱼油后血脂、载脂蛋白、血小板聚集率、血粘度等指标的变化，探讨鱼油在临床治疗中的价值。结果显示：服用鱼油后血清甘油三酯（TG）水平显著下降，总有效率66．7％，平均下降37．1％（P＜0.01）；总胆固醇（TC）水平降低，总有效率53．3％，平均下降16．0％（P＜0．01）；而高密度脂蛋白胆固醇（HDL－C），低密度脂蛋白胆固醇（LDL－C），载脂蛋白A1及B（apoA1，apoB）水平无明显变化；但HDL－C／TC，HDL2－C／HDL3－C，apeA1／apoB比值服药前后差异显著（均为P＜0．05）。服药后血小板聚集率、血粘度、纤维蛋白原含量明显下降（P＜0．05，0．01）。研究结果说明鱼油制剂（EPA＋DHA840mg／d）能有效调整血脂水平，以降TC效果明显；显著改善血小板功能及血液流变学指标，从而发挥其抗动脉粥样硬化的作用，在临床治疗中有推广价值。

Effects of daily fish oil supplement on serum lipids, apolipo-protein, platelet aggregation,hemorrheologic variables and plasma fibrinogen were evaluated in thirty hyperlipidemic subjects. Ingestion of fish oil resulted in a 37.1 % decrease in triglyceride(TG) (P<0.01) and a 16. 0% decrease in total cholesterol(TC) (P<0.01). High density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein AI and B (apoAl, apoB) didn't change significantly after treatment of fish oil, but significant decrease in the ratio of HDL-C/TC, HDL2-C/HDL3-C,and apoAI/apoB were observed. Also decreased were the levels of blood viscosity and plasma fibronogen (P<0. 01). Platelet aggregation induced by ADP was inhibited by fish oil. We conclude that fish oil (EPA+DHA 840 mg/d) is a feasible treatment for hyperlipidemic patients and has a beneficial effect on several risk factors of atherosclerosis.